Disc Medicine Inc. (IRON)
NASDAQ: IRON
· Real-Time Price · USD
48.74
-0.77 (-1.56%)
At close: May 05, 2025, 3:59 PM
48.60
-0.29%
After-hours: May 05, 2025, 04:43 PM EDT
-1.56% (1D)
| Bid | 40.8 |
| Market Cap | 1.69B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.36M |
| EPS (ttm) | -3.96 |
| PE Ratio (ttm) | -12.31 |
| Forward PE | -9.54 |
| Analyst | Buy |
| Ask | 49.81 |
| Volume | 227,287 |
| Avg. Volume (20D) | 417,278 |
| Open | 49.40 |
| Previous Close | 49.51 |
| Day's Range | 47.00 - 50.66 |
| 52-Week Range | 28.25 - 68.73 |
| Beta | 2.78 |
About IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, M...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 12, 2020
Employees 84
Stock Exchange NASDAQ
Ticker Symbol IRON
Website https://www.discmedicine.com
Analyst Forecast
According to 10 analyst ratings, the average rating for IRON stock is "Buy." The 12-month stock price forecast is $75, which is an increase of 53.88% from the latest price.
Stock Forecasts6 months ago
+11.21%
Disk Medicine shares are trading higher. HC Wainwr...
Unlock content with
Pro Subscription
6 months ago
+23.59%
Disc Medicine shares are trading higher after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.
